SCHEMBL1768671

SCHEMBL1768671

CCOC(=O)c1ccnc2ccccc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NUDT1 P36639 1/20 0.57
TSHR P16473 1/20 0.56
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
PKM P14618 1/20 0.55
ALDH1A1 P00352 5/20 0.53
RXFP1 Q9HBX9 2/20 0.53
LMNA P02545 1/20 0.53
CYP3A4 P08684 1/20 0.53
HPGD P15428 1/20 0.53
MAPT P10636 3/20 0.52
KDM4E B2RXH2 3/20 0.52
NPSR1 Q6W5P4 1/20 0.52
CDC25B P30305 1/20 0.49
HSD17B10 Q99714 1/20 0.49
TP53 P04637 1/20 0.48
RAB9A P51151 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
POLB P06746 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29523397 1.00 NUDT1 (0.57) NUDT1TSHRMEN1KMT2APKM
SCHEMBL5669102 0.89 TSHR (0.54) NUDT1TSHRMEN1KMT2APKM
SCHEMBL29259654 0.86 ALDH1A1 (0.51) NUDT1MEN1KMT2APKMALDH1A1
SCHEMBL30313610 0.85 TSHR (0.60) TSHRALDH1A1RXFP1LMNACYP3A4
SCHEMBL27605541 0.85 KMT2A (0.44) NUDT1TSHRMEN1KMT2APKM
SCHEMBL30201809 0.84 LMNA (0.50) NUDT1MEN1KMT2APKMALDH1A1
SCHEMBL13610182 0.83 ALDH1A1 (0.62) TSHRALDH1A1RXFP1LMNACYP3A4
SCHEMBL31083564 0.83 SLC22A12 (0.51) NUDT1TSHRMEN1KMT2APKM
SCHEMBL26649707 0.82 KMT2A (0.43) NUDT1MEN1KMT2APKMALDH1A1
SCHEMBL827693 0.82 PSMD14 (0.57) MEN1KMT2APKMALDH1A1RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10224485-B2 Process for preparing a crystalline organic semiconductor material BASF SE (DE) 2019-03-05 US claimed
US-20170012208-A1 ORGANIC SEMICONDUCTOR FORMULATIONS USINVEST LLC 2017-01-12 US claimed
WO-2004072046-A2 QUINOLINE DERIVATIVES AND THEIR USE FOR MODULATION OF LXR ACTIVITY CAREX S.A. (FR) 2004-08-26 WO claimed
EP-3183250-B1 PROCESS FOR PREPARING CRYSTALLINE ORGANIC SEMICONDUCTOR MATERIAL CLAP CO LTD (KR) 2023-10-04 EP disclosed
CN-116745291-A N- (2- (4-cyanothiazolidin-3-yl) -2-oxoethyl) -quinoline-4-carboxamide 阿斯利康(瑞典)有限公司 2023-09-12 CN disclosed
US-20230123928-A1 ORGANIC LIGHT EMITTING DIODE AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME LG DISPLAY CO., LTD. (KR) 2023-04-20 US disclosed
EP-3183757-B1 ORGANIC SEMICONDUCTOR COMPOSITION COMPRISING LIQUID MEDIUM CLAP CO LTD (KR) 2022-05-04 EP disclosed
CN-107004768-B Organic semiconductor composition containing a liquid medium 巴斯夫欧洲公司 2020-08-21 CN disclosed
US-10454037-B2 Organic semiconductor composition comprising a liquid medium BASF SE (DE) 2019-10-22 US disclosed
US-10224485-B2 Process for preparing a crystalline organic semiconductor material BASF SE (DE) 2019-03-05 US disclosed
US-10043978-B2 Organic semiconductor formulations FLEXTERRA, INC. (US) 2018-08-07 US disclosed
WO-2011061292-A1 A PROCESS FOR A PREPARATION OF MARBOFLOXACIN AND INTERMEDIATE THEREOF KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO (SI) 2011-05-26 WO disclosed
WO-2004072046-A2 QUINOLINE DERIVATIVES AND THEIR USE FOR MODULATION OF LXR ACTIVITY CAREX S.A. (FR) 2004-08-26 WO disclosed
EP-0922044-A1 PYRROLO(3,2-C) QUINOLINE DERIVATIVES PHARMACIA & UPJOHN S.p.A. (IT) 1999-06-16 EP disclosed
WO-1998005660-A1 PYRROLO(3,2-C) QUINOLINE DERIVATIVES PHARMACIA & UPJOHN S.P.A. (IT) 1998-02-12 WO disclosed
US-5071987-A Quinoline dyes; colorfastness BASF AKTIENGESELLSCHAFT (DE) 1991-12-10 US disclosed
US-4968803-A FLUORINE AS OXIDANT ALLIED-SIGNAL INC. (US) 1990-11-06 US disclosed
US-4505916-A TRANQUILIZERS PHARMINDUSTRIE (FR) 1985-03-19 US disclosed
US-4433150-A HYPNBOTICS, ANTICONVULSANTS, TRANQUILIZERS, ANTIDEPRESSANTS, SEDATIVES, ANTIARRHYTHMIA AGENTS PHARMINDUSTRIE (FR) 1984-02-21 US disclosed
US-4402961-A Derivatives of 1-(2-,3- or 4-quinolyl)-2- or -3-(2- or 3-piperidyl or -pyrrolidinyl) ethanone or propanone, and their utilization as antiarrhythmics, anticonvulsivants and for the treatment of anxiety PHARMINDUSTRIE (FR) 1983-09-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10454037-B2 Organic semiconductor composition comprising a liquid medium CRY1, NEFM, OR10J3 NUDT1 1733/4885TSHR 2647/4885MEN1 2472/4885
US-10224485-B2 Process for preparing a crystalline organic semiconductor material STOM, SPOP, TTR NUDT1 365/4885TSHR 3267/4885MEN1 722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.